Bio
Zinaida Good, Ph.D. is an instructor working at the interface between systems biology and cancer immunotherapy at Stanford University. Dr. Good’s research with Profs. Crystal L. Mackall and Sylvia K. Plevritis is focused on investigating why chimeric antigen receptor (CAR) T cell immunotherapies succeed or fail in patients, and she has recently identified CAR T regulatory cells as a correlate of progression following CD19-CAR therapy for large B cell lymphoma. Dr. Good earned her Ph.D. in Computational & Systems Immunology from Stanford University, where she trained with Profs. Garry P. Nolan and Sean C. Bendall and defined methods to build and leverage lymphocyte differentiation trajectories in health and cancer. Her background is in experimental immunology and oncology and combines 2 years of experience working in Discovery Oncology at Genentech with B.S. and M.S. degrees in Microbiology & Immunology from the University of British Columbia, where she investigated the mechanisms of T cell memory with Prof. Michael R. Gold. Dr. Good’s work includes 4 first-author papers (Nature Medicine 2018 & 2022, Nature Biotechnology 2019, Trends in Immunology 2019), 12 co-authored papers (including Nature 2019 & 2022, Science 2021, Nature Methods 2016 & 2022), and 2 patent applications. Her academic potential has been recognized by prestigious postdoctoral fellowships (2018 Parker Institute for Cancer Immunotherapy Scholar, 2020 Stanford Cancer Institute Fellow), a career development award (2023 Parker Institute for Cancer Immunotherapy Bridge Fellow), and she has been named an Arthur and Sandra Irving Cancer Immunology Fellow in 2022. Dr. Good is preparing to launch an independent research program with a long-term goal to understand and enhance engineered cellular immunotherapies for patients with cancer.
